Male Breast Cancer: It&amp;rsquo;s Time for Evidence Instead of Extrapolation

Giordano, Sharon H.

doi:10.1159/000153894

Cited by 19 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its rarity, there have been no prospective randomized clinical trials of MBC patients (2). Clinical management of MBC is guided by research on the disease in females or by data from small case studies.…”

Section: Introductionmentioning

confidence: 99%

Male breast cancer: A retrospective study comparing survival with female breast cancer

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract.Male breast cancer is a rare disease. The aim of this study was to compare overall survival (OS) and disease-free survival (DFS) in a group of matched males and females with breast cancer. The clinical data and survival status of 42 operable male breast cancer (MBC) cases treated at the Central Hospital of Tai'an from 1982 to 2006 were collected. Each MBC patient recorded in the database was matched with two female breast cancer (FBC) patients. Matching was conducted based on age, year of diagnosis, stage and pathology. SPSS 16.0 software was used for statistical analysis. The Chi-square test was used for the categorical data, the Kaplan-Meier method was applied to analyze survival and the log-rank test was used to compare curves between the groups. P<0.05 was considered to indicate a statistically significant difference. The 42 MBC patients were matched with 84 FBC patients. The mean age at diagnosis was 58.0±11.3 years for males and 57.1±10.6 years for females, and the median follow-up time was 64 months (range, 5-262 months) for males and 71 months (range, 29-283 months) for females. Significant differences were identified for tumor location, hormone receptor status, adjuvant chemotherapy and hormone therapy between the two groups. Monofactorial analysis demonstrated that tumor size, lymph node status and AJCC stage were prognostic factors in MBC patients. The 5-and 10-year DFS rates were 61.2 and 40.7% for males, and 68.7 and 43.0% for females, respectively. The 5-and 10-year OS rates were 75.3 and 52.3% for males, and 82.9 and 63.2% for females, respectively. In our study, male breast carcinoma patients had a worse prognosis compared to female breast carcinoma patients which may be due to the deficiency of adjuvant chemotherapy and endocrine therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Male breast cancer: A retrospective study comparing survival with female breast cancer

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…2, 3 Consequently, the management of breast cancer among men is generalized from the management of breast cancer in women. 3,4 However, without evidence-based data to support this female-to-male extrapolation, epidemiologic comparisons become an alternative source of information.…”

Section: Introductionmentioning

confidence: 99%

“…3,4 However, without evidence-based data to support this female-to-male extrapolation, epidemiologic comparisons become an alternative source of information. 5 Therefore, to compare and contrast population-based incidence, mortality, and survival rates for male and female breast cancers, we examined breast cancer cases in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Database from 1973 through 2005.…”

Section: Introductionmentioning

confidence: 99%

Male Breast Cancer: A Population-Based Comparison with Female Breast Cancer.

2009

View full text Add to dashboard Cite

A B S T R A C T PurposeBecause of its rarity, male breast cancer is often compared with female breast cancer. Patients and MethodsTo compare and contrast male and female breast cancers, we obtained case and population data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program for breast cancers diagnosed from 1973 through 2005. Standard descriptive epidemiology was supplemented with age-period-cohort models and breast cancer survival analyses. ResultsOf all breast cancers, men with breast cancer make up less than 1%. Male compared with female breast cancers occurred later in life with higher stage, lower grade, and more estrogen receptor-positive tumors. Recent breast cancer incidence and mortality rates declined over time for men and women, but these trends were greater for women than for men. Comparing patients diagnosed from 1996 through 2005 versus 1976 through 1985, and adjusting for age, stage, and grade, cause-specific hazard rates for breast cancer death declined by 28% among men (P ϭ .03) and by 42% among women (P Ϸ 0). ConclusionThere were three intriguing results. Age-specific incidence patterns showed that the biology of male breast cancer resembled that of late-onset female breast cancer. Similar breast cancer incidence trends among men and women suggested that there are common breast cancer risk factors that affect both sexes, especially estrogen receptor-positive breast cancer. Finally, breast cancer mortality and survival rates have improved significantly over time for both male and female breast cancer, but progress for men has lagged behind that for women.

show abstract

“…Epidemiological studies showed that the rate of male breast cancer is 0.5-1% in most Western countries, and 6% or more in Tanzania and Central Africa [1,2]. The reasons for this geographic variability remain unclear.…”

Section: Discussionmentioning

confidence: 99%

“…Breast cancer is very rare in men, accounting for less than 1% of all breast cancers and less than 1% of all cancers in men [1,2]. The occurrence of occult breast cancer in men is even less common [3,4].…”

Section: Introductionmentioning

confidence: 99%

Axillary Metastasis as the First Manifestation of Occult Breast Cancer in a Male Patient

Wang²,

Wei³

et al. 2009

Breast Care

View full text Add to dashboard Cite

Background: The aim of this study was to investigate the clinicopathologic features of male breast cancer. Case Report: We present the clinicopathologic data of a 72year-old male patient with occult breast cancer, who was diagnosed and underwent surgery in our hospital. The diagnosis was confirmed by histological examination, and the patient underwent modified radical mastectomy and axillary dissection. The histological examination showed no tumor foci in the resected breast tissue, but 2 of 15 dissected axillary lymph nodes were invaded by infiltrating ductal carcinoma. Immunohistochemistry staining was negative for both estrogen and progesterone receptors, but showed expression of p53 protein (+++), proliferating cell nuclear antigen (PCNA) (+++), Bcl-2 on-coprotein (+++), nm23 protein (++), multidrug resistance protein (MRP) (++), and human epidermal receptor (HER2) oncoprotein (+++). 24 months after being diagnosed, the patient is alive without any residual or metastatic disease. Conclusions: Breast cancer is very rare in men, and the occurrence of occult breast cancer is even less common. Axillary metastases can present as the first manifestation of breast cancer in a male.

show abstract

Male Breast Cancer: It’s Time for Evidence Instead of Extrapolation

Cited by 19 publications

References 13 publications

Male breast cancer: A retrospective study comparing survival with female breast cancer

Male breast cancer: A retrospective study comparing survival with female breast cancer

Male Breast Cancer: A Population-Based Comparison with Female Breast Cancer.

Axillary Metastasis as the First Manifestation of Occult Breast Cancer in a Male Patient

Contact Info

Product

Resources

About